190 related articles for article (PubMed ID: 38038129)
1. CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
Wang S; Iyer R; Han X; Wei J; Li N; Cheng Y; Zhou Y; Gao Q; Zhang L; Yan M; Sun Z; Fang D
J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 38038129
[TBL] [Abstract][Full Text] [Related]
2. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
3. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
5. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
6. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.
Lu M; Wang K; Ji W; Yu Y; Li Z; Xia W; Lu S
Cell Immunol; 2022 Sep; 379():104577. PubMed ID: 35870429
[TBL] [Abstract][Full Text] [Related]
7. ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers.
Xiao D; Zeng T; Zhu W; Yu ZZ; Huang W; Yi H; Lu SS; Feng J; Feng XP; Wu D; Wen Q; Zhou JH; Yuan L; Zhuang W; Xiao ZQ
Cancer Immunol Res; 2023 Oct; 11(10):1367-1383. PubMed ID: 37566399
[TBL] [Abstract][Full Text] [Related]
8. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
9. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
10. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
[TBL] [Abstract][Full Text] [Related]
11. ATXN3 deubiquitinates YAP1 to promote tumor growth.
Wang S; Liu K; Han X; Cheng Y; Zhao E; Brat DJ; Sun Z; Fang D
Am J Cancer Res; 2023; 13(9):4222-4234. PubMed ID: 37818078
[TBL] [Abstract][Full Text] [Related]
12. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
Kalantari Khandani N; Ghahremanloo A; Hashemy SI
J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
[TBL] [Abstract][Full Text] [Related]
13. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
14. CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.
Niu X; Wang W; Liang T; Li S; Yang C; Xu X; Li L; Liu S
Cancer Sci; 2022 Jan; 113(1):28-40. PubMed ID: 34727389
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
16. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
[TBL] [Abstract][Full Text] [Related]
17. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
19. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1.
Zhu D; Xu R; Huang X; Tang Z; Tian Y; Zhang J; Zheng X
Cell Death Differ; 2021 Jun; 28(6):1773-1789. PubMed ID: 33328570
[TBL] [Abstract][Full Text] [Related]
20. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
